Difficulty: Medium
Average Score: 72%
Practice
In hyperkalemia, which of the following treatments antagonizes the direct effect of potassium on the heart?
Correct answer
C
Rationale
In the context of pediatric nursing, understanding the management of hyperkalemia is crucial for providing safe and effective care to pediatric patients. In hyperkalemia, the elevated levels of potassium can lead to dangerous cardiac effects, including arrhythmias and cardiac arrest. The correct answer, IV calcium gluconate (Option C), antagonizes the direct effect of potassium on the heart by stabilizing the cardiac cell membrane potential. Calcium helps counteract the depolarizing effect of potassium, thereby reducing the risk of life-threatening cardiac complications.
Option A, cation exchange resin, is used to remove potassium from the body by exchanging it with other cations in the gastrointestinal tract. While this treatment can lower potassium levels, it does not directly counteract the effects of hyperkalemia on the heart like calcium gluconate does.
Option B, inhaled Beta 2 agonist, is more commonly used in conditions like asthma to cause bronchodilation. It does not play a significant role in managing hyperkalemia and its cardiac effects.
Option D, IV insulin/glucose mixture infusion, works by promoting the movement of potassium from the extracellular space into the cells. While this treatment can help lower potassium levels overall, it does not specifically target the direct cardiac effects of hyperkalemia like calcium gluconate does.
Educationally, understanding the rationale behind choosing IV calcium gluconate in hyperkalemia is crucial for pediatric nurses to provide timely and appropriate interventions to prevent cardiac complications in pediatric patients. By grasping the pharmacological actions of different treatments, nurses can make informed clinical decisions to optimize patient outcomes and safety.
Option A, cation exchange resin, is used to remove potassium from the body by exchanging it with other cations in the gastrointestinal tract. While this treatment can lower potassium levels, it does not directly counteract the effects of hyperkalemia on the heart like calcium gluconate does.
Option B, inhaled Beta 2 agonist, is more commonly used in conditions like asthma to cause bronchodilation. It does not play a significant role in managing hyperkalemia and its cardiac effects.
Option D, IV insulin/glucose mixture infusion, works by promoting the movement of potassium from the extracellular space into the cells. While this treatment can help lower potassium levels overall, it does not specifically target the direct cardiac effects of hyperkalemia like calcium gluconate does.
Educationally, understanding the rationale behind choosing IV calcium gluconate in hyperkalemia is crucial for pediatric nurses to provide timely and appropriate interventions to prevent cardiac complications in pediatric patients. By grasping the pharmacological actions of different treatments, nurses can make informed clinical decisions to optimize patient outcomes and safety.